Engineered immune cells take on tough leukemia
Disease control
Recruiting now
This study is testing a new treatment called UCART22 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. UCART22 uses donor immune cells that are engineered in a lab to recognize and attack …
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Jun 26, 2026 14:53 UTC